Cytokinetics CYTK Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's long-term debt?
- Cytokinetics (CYTK) reported long-term debt of $247.21M in Q1 2026.
- How has Cytokinetics's long-term debt changed year-over-year?
- Cytokinetics's long-term debt increased by 168.6% year-over-year, from $92.03M to $247.21M.
- What is the long-term trend for Cytokinetics's long-term debt?
- Over 5 years (2020 to 2025), Cytokinetics's long-term debt has grown at a 39.8% compound annual growth rate (CAGR), from $46.21M to $246.38M.
- What does long-term debt mean?
- Total debt that is not due to be paid back for at least a year.
- How do you interpret long-term debt?
- High levels increase financial leverage and interest expense, while low levels indicate a conservative capital structure.
- How does long-term debt compare across companies?
- Biotech companies often carry varying levels of debt depending on their stage of clinical development.